MK-2866 (Ostarine) vs Myostatin Inhibitor
A side-by-side research comparison of MK-2866 (Ostarine) and Myostatin Inhibitor across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MK-2866 (Ostarine) | Myostatin Inhibitor |
|---|---|---|
| Full name | Ostarine / Enobosarm (MK-2866) | Myostatin Inhibitor Peptides (Anti-GDF-8) |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational (not approved; banned in sport) | Research compound |
| Mechanism | Selectively binds androgen receptors in muscle and bone tissue, stimulating anabolic (muscle-building) signaling while having relatively less effect on the prostate and other androgen-sensitive tissues than testosterone. | Propeptide mimics bind mature myostatin; peptide aptamers block ActRIIB; small antagonists compete for receptor. All prevent myostatin-mediated suppression of muscle growth. |
| Molecular weight | 389.33 Da | 2,000-15,000 Da (varies) |
| Half-life | ~24 hours | 4-48 hours (design-dependent) |
| Bioavailability | Oral | Variable (SubQ) |
| Typical dose | Commonly cited 10-25 mg/day (research) | 50-500 mcg |
| Frequency | Once daily | 3-7x per week |
| Route | Oral | Subcutaneous |
MK-2866 (Ostarine) reported benefits
- Lean muscle preservation/gain
- Bone density support (research)
- Less androgenic than steroids
- Studied for muscle wasting
Myostatin Inhibitor reported benefits
- Muscle growth promotion
- Strength increase
- Myostatin blockade
- Muscle wasting treatment potential
- Metabolic improvement
Related comparisons
Research and educational reference only. Not medical advice.